Predictors of excessive short-acting β₂-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database.

"Conflict of interest P. D¹browiecki received consultancy fees from GlaxoSmithKline, Sandoz, lecture fees from AstraZeneca, Polpharma, Berlin Chemie, Adamed, and financial or material grants for research from Novartis. D. Brzostek is a permanent employee of AstraZeneca. A. D¹browski received consultancy fees from AstraZeneca. R. Dobek received consultancy fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, lecture fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, GlaxoSmithKline, and financial or material grants for research (as a clinical trial principal investigator) from Genentech-Roche, Gossammer Bio. R. Gawlik received lecture fees from AstraZeneca, HAL Allergy, ALK, Novartis, Chiesi, Allergopharma, Mylan. I. Kupryś-Lipińska received consultancy fees fromGlaxoSmithKline, AstraZeneca, Novartis, lecture fees from AstraZeneca, Chiesi, GlaxoSmithKline, Nexter, Novartis, financial or material grants for research from AstraZeneca, and congress fees from Zentiva. A. Mastalerz-Migas received consultancy and lecture fees from AstraZeneca. M. L. Kowalski received consultancy fees from AstraZeneca, GlaxoSmithKline, Uriach, lecture fees from AstraZeneca, GlaxoSmithKline, Sandoz, Chiesi, Novartis, Uriach, and financial or material grants for research from GlaxoSmithKline. The remaining authors declare no relevant conflict of interests."

"This study was supported by an educational grant from AstraZeneca Pharma Poland."